[1] Delektorskaya VV, Perevoshchikov AG, Kushlinskii NE.Immunohistological study of NM 23 and C-erbB-2 expression in primary tumor and metastases of colorectal adenocarcinoma[J]. Bull Exp Biol Med, 2003, 135(5):489-494. [2] Orr MS, O'Connor PM, Kohn KW. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells[J].Natl Cancer Inst , 2000 ,92(12):987-994. [3] Karnes WE Jr, Weller SG, Adjei PN, et al .Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells[J].Gastroenterology, 1998,114(5):930-939. [4] 薄挽澜,胡风丽,翟博,等.c-erbB-2, bcl-2和P53在结直肠肿瘤中的表达及其临床意义[J].胃肠病学.2007,12(5):279-282. [5] 李志刚,黄文广,李杰, 等.转化生长因子βII和c-erbB-2基因在结直肠癌中的表达[J].中国普通外科学杂志,2003,12(4): 299-301. [6] 宗星月,李进伟.针对EGFR和VEGF/VEGFR靶点的肿瘤分子靶向药物研究进展[J].中国实用内科杂志, 014,34(62) :62. [7] Akkiprik M,Celikel CA,Dusunceli F, et al.Relationship between overexpression of ras p21 oncoprotein and K-ras codon 12 and 13 mutations in Turkish colorectal cancer patients[J].Turk Gastroenterol,2008,19(1):22-27. [8] Ohta M, Seto M, Ljichi H, et al .Decreased expression of the Ras GTPase-activating protein RASAL 1isassociated withcolor-ectaltumorprogression[J].Gastroenterology,2009,136(1):206-216. [9] Ma BB, Mo F, Tong JH, et al .Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cance[J].Asia Pac Clin Oncol, 2015 ,11(2):160-169. [10] 高静,孙志伟,李艳艳,等.中国结直肠癌患者966中KRAS和BRAF基因突变分析[J].中华病理学杂志,2012,41(9):579-583. [11] Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer[J].Genes Dis, 2015, 2(1):4-12. [12] Irahara N, Baba Y, Nosho K, et al . NRAS mutations are rare in colorectal cancer[J].Diagn Mol Pathol, 2010,19(3):157-163. [13] Palomba G, Doneddu V, Cossu A, et al . Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study[J].Transl Med, 2016,14(1):292 .
2017, Vol. 23 
冀公网安备13080202000677号